Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

Posted by rob on May 23, 2011 under Uncategorized | Comments are off for this article

CONCLUSIONS:Deletions of derivative chromosome 9 do not appear to be an independent risk factor for survival among patients with CML in chronic phase receiving second generation TKIs. Cancer 2011;. © 2011 American Cancer Society. (Source: Cancer)
More